Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.
By T. Mazzone, P. Meyer, S. Feinstein, M. Davidson, G. Kondos, R. D'Agostino, Alfonso T. Perez, J. Provost, S. Haffner. Journal of the American Medical Association (JAMA), 2006
717 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine, Endocrinology, Diabetes and Metabolism
View Paper: https://www.semanticscholar.org/paper/ad5b1e57e45778cab1654d68009264c18fd714c8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
In Endocrinology, Diabetes and Metabolism
Citations in the corpus
- From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus (2009, result): “These molecular observations help to explain the recent results from the CHICAGO (Carotid Intima-Media Thickness in Atherosclerosis Using Pioglitazone) (167) and PERISCOPE (Pioglitazone Effect on Regression of Intravascular Sonographic Coronary Obstruction Prospective Evaluation) (168) studies, in w”
- Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. (2008, background): “Furthermore, a well-controlled randomized trial in another vascular bed, the carotid artery, demonstrated an absence of progression of intimal medial thickness for pioglitazone-treated patients and progression in glimepiride-treated patients.(7) A placebo-controlled clinical outcomes trial investiga”